Investigational agents in development for the treatment of ovarian cancer - Wikidata - wikimedia - TriplyDB

Investigational agents in development for the treatment of ovarian cancer

Investigational agents in development for the treatment of ovarian cancer

http://www.wikidata.org/entity/Q33920800

about

Chemotherapy of ovarian cancer in elderly patients Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Can Some Marine-Derived Fungal Metabolites Become Actual Anticancer Agents?'BRCAness' and its implications for platinum action in gynecologic cancer.RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.The significance of the alteration of 8-OHdG in serous ovarian carcinoma.INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.Genetic changes in nonepithelial ovarian cancer.Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors.Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.Salidroside induces apoptosis in human ovarian cancer SKOV3 and A2780 cells through the p53 signaling pathway.

P2860

Q26771397-1001FEAF-FA57-4A02-8B97-419532C20931 Q27024235-38640453-3D26-4F7B-8995-9713777E65B7 Q35790810-D193BEF8-189B-4213-8557-B19AF6D83F6E Q36380704-188A57AE-9E4D-4E5E-BA6F-F47568E820D0 Q36413165-94711492-CD64-43F3-9262-545A93E65DAA Q37420444-A05BAF56-23DA-4B96-8975-4544C2B0E812 Q37502372-E72FD544-8F36-45B4-A1C0-0BC879CD0E4C Q37720579-9234607B-D184-4DA6-988A-89F8350B39F5 Q38123207-928D4AE5-2365-43E5-9ECF-D257C134001F Q54645627-67112BB5-CA24-4C24-90BF-86D2428FC090 Q54993659-A4F9ABC2-71F5-4EA0-A0F0-B6D4155C32CF Q55311350-47705359-A5E9-4A67-9610-EA6EA5C3658E

P2860

Investigational agents in development for the treatment of ovarian cancer

http://www.wikidata.org/entity/Q33920800

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Investigational agents in development for the treatment of ovarian cancer

@ast

Investigational agents in development for the treatment of ovarian cancer

@en

type

label

Investigational agents in development for the treatment of ovarian cancer

@ast

Investigational agents in development for the treatment of ovarian cancer

@en

prefLabel

Investigational agents in development for the treatment of ovarian cancer

@ast

Investigational agents in development for the treatment of ovarian cancer

@en

P1433

Q33920800-03495ED8-5CA1-4BC1-921A-4A538756B4E7

P1476

Q33920800-1CE6D0DB-44F5-468A-8FE7-858C5B2C54CD

P2093

Q33920800-06191511-7A79-4076-A6AB-46041A97CCA2

Q33920800-A74D6CD4-0B07-4B9D-9384-BD4E51133F3A

Q33920800-B10101D6-EAD0-4315-A7DD-223C3A158C4F

P2860

Q33920800-0046BEBE-3A1C-48CA-9222-B3455B84A5C7

Q33920800-00E00C6A-4757-4291-B97A-6B708579D896

Q33920800-01A76FD9-289E-4CB3-BF0E-A6D9B7EFFE31

Q33920800-06C1C6D7-CA34-4A04-A693-270BF2E34988

Q33920800-0B657B1B-2B01-4F2B-8507-C5F267044C48

Q33920800-0BC15654-53EB-43D4-ACCD-455DAD9E4EF2

Q33920800-0FC1429F-815D-4039-97A9-50058A9A3171

Q33920800-14D7B119-463C-4ACD-8652-3A7C662647FC

Q33920800-1A6A0A30-D2DA-4B35-9383-7ED84CD01945

Q33920800-1BB299F1-2636-4D6F-A387-364F99B3512A

P2888

Q33920800-C34B9A2E-25D9-4E08-95EC-045C30573D1A

P304

Q33920800-2F932EC0-BB92-4A1C-8D5A-79BAC548578F

P31

Q33920800-734E7567-B5A5-4233-87E8-173608DC89FF

P356

Q33920800-3C792F27-376A-4EB3-AAF8-0C33D01907A7

P433

Q33920800-56B50600-8953-48C6-AACD-03FFB914686E

P478

Q33920800-41A7DCAC-1FDE-4EE2-AF14-E94AA43CFE82

P577

Q33920800-69EB63F4-84C9-42FD-9B2B-E7E3E474436C

P6179

Q33920800-1B45A531-AF7A-4018-BFB8-DD04754C796A

P698

Q33920800-B2D163E1-8EE0-499B-8411-DD32ACA24AFB

P921

Q33920800-F3EB1ABB-9449-4198-AF2B-BDEFD05BA34F

P932

Q33920800-9D398570-3658-4001-91AD-F53CB75734CF

P356

S10637-012-9837-3

P1433

Investigational New Drugs

P1476

Investigational agents in development for the treatment of ovarian cancer

@en

P2093

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

Shannon N Westin

http://www.w3.org/2001/XMLSchema#string

Thomas J Herzog

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Modes of resistance to anti-angiogenic therapy

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

Targeting the mTOR signaling network for cancer therapy

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Integrated genomic analyses of ovarian carcinoma

Synthetic lethality--a new direction in cancer-drug development

P2888

s10637-012-9837-3

P304

213-229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-012-9837-3

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005672881

http://www.w3.org/2001/XMLSchema#string

P698

22661305

http://www.w3.org/2001/XMLSchema#string

P921

P932

4103697

http://www.w3.org/2001/XMLSchema#string